Machinery & Materials
Logistics & Cold Chain
More from Patheon
1.3 Million Birth Control Pills Recalled
Endo recalls 162 lots of subpotent birth control pills manufactured by Patheon.
Nov 14th, 2016
Patheon sells clinical packaging business to Bellwyck
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions, a private company with 20 years experience providing clinical trial and contract services for secondary packaging.
Sep 6th, 2012
Patheon Announces a Change to its PDS Management Structure
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that Mark J.
Aug 14th, 2012
Patheon Forms "Patheon Certified Consultants" Service
Patheon, the world¹s leading global provider of contract development and manufacturing services, announced today the formation of Patheon Certified Consultants, a new consulting capability comprised of industry veterans who provide a unique service to emerging biotech and pharmaceutical companies, as well as their investors, to help address early-, mid- and late-stage CMC questions in drug development•€¹from strategic to practical.
Apr 18th, 2012
Patheon Adds Soft Gel Capsule Capabilities Through New Partnership with Procaps, S.A. (now United Caps)
Patheon and PROCAPS S.A. are pleased to announce an agreement to provide the pharmaceutical industry a new world-class line of prescription pharmaceutical soft-gel product development and manufacturing services.
Jan 20th, 2012
Patheon announces change to its Board of Directors
Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, is pleased to announce the appointment of Michel Lagarde, Principal, JLL Partners, to its Board of Directors.
Dec 22nd, 2011
Patheon signs three year $18 million development agreement with Boehringer Ingelheim
Patheon, Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Boehringer Ingelheim, a leading globally operating pharmaceutical corporation, has awarded it two projects with combined revenue of more than $18 million over a three year period of time.
Oct 21st, 2011